Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Angina Pectoris Drugs Market by Type, by Drugs, by Route of Administration, by End-Users, and By Region" report has been added to ResearchAndMarkets.com's offering.
The latest comprehensive research publication on the Angina Pectoris Drugs Market shines a light on the significant growth potential forecasted through 2034. This in-depth analysis delves into a range of crucial factors contributing to market expansion, with a particular focus on the evolving dynamics of angina management and pharmaceutical innovation.
The surging demand for angina pectoris treatments is propelling the global market, as the need for effective management of cardiovascular conditions becomes increasingly prevalent. The growing geriatric population, widespread cardiovascular diseases, and developments in the pharmaceutical industry are key drivers of this upsurge.
The study segments the angina pectoris drugs market by type, route of administration, end-users, and geographic regions to offer a detailed perspective on the diverse landscape. By type, stable angina has been acknowledged as the dominant share-holder, reflecting the chronic nature and commonality of the condition. Unstable angina, however, is anticipated to exhibit the fastest growth due to early intervention imperatives.
Hospital-based end-users maintain a significant slice of the market, attributed to their pivotal role in administering acute care. Contrastingly, homecare settings are predicted to burgeon at an accelerated rate, driven by the trend toward patient-centric models and telehealth advancements.
Market Segmentation Highlights
- By Drugs: The beta-adrenergic blocking agents dominate, yet antiplatelet agents show promising growth trajectories.
- By Route of Administration: Oral administration remains the front-runner due to its convenience, whereas transdermal methods are catching up rapidly.
- By Region: The North American market leads in revenue generation, while the Asia Pacific is the fastest-growing region, propelled by augmenting healthcare infrastructure.
In considering geographic landscapes, the analyses offer insights into the market outlook for regions such as North America and the Asia Pacific. North America's strong healthcare system and heightened awareness about heart health underpin its substantial market share, whereas the Asia Pacific is forecasted to soar, thanks to improving health services and increasing health awareness.
Looking forward, the publication provides an exhaustive overview of factors that will steer the market from 2023 to 2034. It showcases the preparedness of the global angina pectoris drugs market to meet the advancing needs of a diverse patient demographic and adapt to the shifting healthcare environment.
The research presents an invaluable asset for stakeholders, investors, healthcare professionals, and policymakers, setting the stage for informed decisions and strategic planning in the angina pectoris drugs domain.
For additional details on the analysis and to access the full breadth of market projection data, interested parties are directed towards the original research publication.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value (USD) in 2023 | $10.17 Billion |
| Forecasted Market Value (USD) by 2034 | $18.54 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
Key Topics Covered
- Introduction:
- Market Definition
- Global Angina Pectoris Drugs Market Overview
- Executive Summary
- Market Environment Analysis:
- Porter's 5 Forces Analysis
- PESTEL Analysis
- SWOT Analysis
- Market Dynamics:
- Drivers Analysis
- Restraints Analysis
- Opportunities Analysis
- Threats Analysis
- Trend Analysis
- COVID-19 Impact Analysis
- Angina Pectoris Drugs Market: Type Estimates & Trend Analysis
- Stable Angina
- Unstable Angina
- Prinz-metal's Angina
- Angina Pectoris Drugs Market: Drugs Estimates & Trend Analysis
- Nitrates
- Antiplatelet Agents
- Beta-adrenergic Blocking Agents
- Calcium Channel Blockers
- Anti-ischemic Agents
- Statins
- Antihypertensive Agents
- Others
- Angina Pectoris Drugs Market: Route of Administration Estimates & Trend Analysis
- Oral
- Parenteral
- Transdermal
- Others
- Angina Pectoris Drugs Market: End-user Estimates & Trend Analysis
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Regional Market Analysis:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Competitor Analysis:
- Company Market Share Analysis, 2023
- Major Recent Developments
- Company Profiles:
- Profiles of major companies in the market
- Conclusion
- Recommendations
Companies Mentioned
- Pfizer Inc.
- AstraZeneca PLC
- Merck & Co. Inc.
- Novartis International AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Johnson & Johnson
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Bayer AG
- AbbVie Inc.
- Daiichi Sankyo Company
- Limited
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
For more information about this report visit https://www.researchandmarkets.com/r/ki0pgt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
